Vanda Pharma Q3 sales rises, driven by Fanapt growth

Vanda Pharmaceuticals

29/10/2025 20:10

Overview

Vanda Q3 total net product sales rise 18% yr/yr, driven by Fanapt growth

Company reports Q3 net loss of $22.6 mln, up from $5.3 mln last year

Vanda advancing pipeline with multiple FDA reviews and submissions expected

Outlook

Vanda revises 2025 revenue guidance to $210-$230 mln from $210-$250 mln

Company expects year-end 2025 cash between $260 mln and $290 mln

Bysanti NDA for bipolar I disorder under FDA review, action date Feb 21, 2026

Result Drivers

FANAPT SALES - Fanapt sales increased by 31% in Q3 2025, driven by a 35% increase in prescriptions

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.38
Q3 Net Income
-$22.58 mln
Q3 Basic EPS
-$0.38
Q3 Operating Expenses
$87.54 mln
Q3 Operating Income
-$31.28 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Vanda Pharmaceuticals Inc is $13.00, about 57.1% above its October 28 closing price of $5.58

Press Release: ID:nPn4dmPfxa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)